We are live on ! Find out more
SM

Sabby Management Portfolio holdings

AUM $45.1M
1-Year Est. Return 74.25%
This Fund
S&P 500
This Quarter Est. Return
-6.02%
1 Year Est. Return
-74.25%
3 Year Est. Return
-95.86%
5 Year Est. Return
-99.36%
10 Year Est. Return
-99.46%
AUM
$1.53B
AUM Growth
-$325M
Cap. Flow
-$296M
Cap. Flow %
-19.34%
Top 10 Hldgs %
65.86%
Holding
300
New
43
Increased
68
Reduced
83
Closed
84

Top Buys

Rank Stock Value
1
BMY icon
Bristol-Myers Squibb
BMY
+$95.6M
2
TSRO
TESARO, Inc.
TSRO
+$7.45M
3
SGEN
Seagen Inc. Common Stock
SGEN
+$5.41M
4
MBOT icon
Microbot Medical
MBOT
+$4.73M
5
UTHR icon
United Therapeutics
UTHR
+$4.46M

Top Sells

Rank Stock Value
1
AMGN icon
Amgen
AMGN
+$6.09M
2
IONS icon
Ionis Pharmaceuticals
IONS
+$5.39M
3
MTFB
Motif Bio plc ADRs
MTFB
+$4.6M
4
OTIC
Otonomy, Inc.
OTIC
+$3.19M
5
PALI icon
Palisade Bio
PALI
+$2.63M

Sector Composition

Rank Sector Weight
1 Healthcare 13%
2 Materials 0.27%
3 Financials 0.11%
4 Consumer Staples 0.03%
5 Consumer Discretionary 0.01%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CHRS icon
226
Coherus Oncology
CHRS
$219M
– –
-93,308
Closed -$1.97M
CHRS icon
227
PUT
Coherus Oncology
CHRS
$219M
– –
-1,336
Closed -$2.83M
CVM icon
228
CEL-SCI Corp
CVM
$20.4M
– –
-2,400
Closed -$154K
ENLV icon
229
Enlivex Ltd
ENLV
$36.2M
– –
-367
Closed -$167K
ESPR
230
CALL
DELISTED
Esperion Therapeutics
ESPR
– –
-320
Closed -$1.13M
EXEL icon
231
CALL
Exelixis
EXEL
$14.1B
– –
-1,700
Closed -$3.68M
EXEL icon
232
PUT
Exelixis
EXEL
$14.1B
– –
-500
Closed -$1.08M
EYPT icon
233
EyePoint Inc
EYPT
$989M
– –
-20,510
Closed -$353K
HCA icon
234
CALL
HCA Healthcare
HCA
$91.6B
– –
-750
Closed -$6.67M
HES
235
CALL
DELISTED
Hess
HES
– –
-250
Closed -$2K
IONS icon
236
Ionis Pharmaceuticals
IONS
$9.01B
– –
-115,694
Closed -$5.39M
IOVA icon
237
CALL
Iovance Biotherapeutics
IOVA
$2.07B
– –
-195
Closed -$145K
JAZZ icon
238
CALL
Jazz Pharmaceuticals
JAZZ
$16.2B
– –
-334
Closed -$4.85M
LRMR icon
239
CALL
Larimar Therapeutics
LRMR
$381M
– –
-12
Closed -$69K
LRMR icon
240
Larimar Therapeutics
LRMR
$381M
– –
-11,943
Closed -$668K
LXRX icon
241
CALL
Lexicon Pharmaceuticals
LXRX
$1.03B
– –
-1,563
Closed -$2.24M
LXRX icon
242
Lexicon Pharmaceuticals
LXRX
$1.03B
– –
-28,626
Closed -$443K
MBRX icon
243
Moleculin Biotech
MBRX
$9.82M
– –
-44
Closed -$117K
MNKD icon
244
MannKind Corp
MNKD
$1.21B
– –
-209,292
Closed -$269K
OEF icon
245
CALL
iShares S&P 100 ETF
OEF
$19.7B
– –
-5,000
Closed -$68.7M
OPK icon
246
PUT
Opko Health
OPK
$1.07B
– –
-126
Closed -$101K
PALI icon
247
Palisade Bio
PALI
$339M
– –
-6
Closed -$2.63M
PBYI icon
248
Puma Biotechnology
PBYI
$401M
– –
-10,600
Closed -$394K
PBYI icon
249
PUT
Puma Biotechnology
PBYI
$401M
– –
-626
Closed -$2.33M
PTCT icon
250
PTC Therapeutics
PTCT
$6.18B
– –
-54,736
Closed -$737K
8 9
10
11 12

Similar funds

CG
Circumference Group Little Rock, Arkansas $44.6M AUM 5.21% 1-Year Est. Return
OC
Optimas Capital Central, Hong Kong $44.5M AUM 24.43% 1-Year Est. Return
ICCON
Investment Counsel Company of Nevada Las Vegas, Nevada $44.5M AUM 21.97% 1-Year Est. Return
PCM
Prentice Capital Management Greenwich, Connecticut $45.7M AUM 2.65% 1-Year Est. Return
CAS
CTC Alternative Strategies Chicago, Illinois $44M AUM 43.15% 1-Year Est. Return
CM
Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return
MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
CTC
Corundum Trust Company Sioux Falls, South Dakota $43.8M AUM 20.07% 1-Year Est. Return

Sabby Management's Q2 2017 Portfolio in Review

As of Q2 2017, Sabby Management held 300 positions worth $1.53B, down 18% from $1.85B the previous quarter. Its ten largest holdings account for 66% of the portfolio.

Sabby Management withdrew a net $296M in Q2 2017, closing 84 positions and reducing 83 holdings. Its most notable exit was Amgen, an estimated $6.09M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 13% of assets, up from 6.3% a quarter earlier, followed by Materials and Financials.

Against the trend, Sabby Management opened a new position in TESARO, Inc. worth $7.19M.

  • Sabby Management's largest Q2 2017 buy was TESARO, Inc.: 51,426 shares worth $7.19M.
  • Sabby Management added most to Bristol-Myers Squibb in Q2 2017, an estimated $95.6M increase.
  • Sabby Management's biggest Q2 2017 reduction was Otonomy, Inc., cutting an estimated $3.19M.
  • Sabby Management fully exited Amgen in Q2 2017, selling an estimated $6.09M.
  • Sabby Management's ten largest holdings make up 66% of its $1.53B portfolio in Q2 2017.
  • Sabby Management opened 43 new positions and closed 84 in Q2 2017.
  • Sabby Management's portfolio value fell 18% quarter-over-quarter to $1.53B.

Based on Sabby Management's 13F filing for Q2 2017, filed 14 Aug 2017.